Holen Sie sich die Stockscreener-App
43.99
2.71%
1.16
Handel nachbörslich:
44.00
0.010
+0.02%
Schlusskurs vom Vortag:
$42.83
Offen:
$42.63
24-Stunden-Volumen:
2.46M
Relative Volume:
0.88
Marktkapitalisierung:
$7.61B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-18.25
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
-2.50%
1M Leistung:
+17.24%
6M Leistung:
+56.44%
1J Leistung:
+75.96%
1-Tages-Spanne:
$42.28
$44.07
1-Wochen-Bereich:
$41.80
$45.48
52-Wochen-Spanne:
$21.72
$45.48
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Vergleichen Sie BBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
43.99 | 7.61B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
10 Biotech Stocks Screaming a Buy - Insider Monkey
Wolfe Research Initiates Coverage on BBIO with Outperform Rating - GuruFocus
Wolfe Research Initiates Coverage on BBIO with Outperform Rating | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Gains Positive Outlook with Strong Transthyreti - GuruFocus
Wolfe Research Initiates Coverage on BridgeBio Pharma With Outperform Rating, $49 Price Target - MarketScreener
BridgeBio (BBIO) Receives Outperform Rating from Wolfe Research | BBIO Stock News - GuruFocus
BridgeBio Pharma stock reaches 52-week high at $40.45 By Investing.com - Investing.com South Africa
BridgeBio Pharma stock reaches 52-week high at $40.45 - Investing.com
BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright - MSN
BridgeBio Pharma’s SWOT analysis: stock poised for growth amid challenges - Investing.com
When the Price of (BBIO) Talks, People Listen - news.stocktradersdaily.com
Cantor Fitzgerald Comments on BBIO FY2026 Earnings - Defense World
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
BridgeBio Pharma (NASDAQ:BBIO) Given New $56.00 Price Target at HC Wainwright - Defense World
Day 8 of Gains Streak for BridgeBio Pharma Stock with 21% Return (vs. 42% YTD) [6/9/2025] - Trefis
BridgeBio stock holds Buy rating, price target at $56H.C. Wainwright - Investing.com Canada
BridgeBio Pharma (BBIO) Sees Price Target Increase by HC Wainwri - GuruFocus
BridgeBio (BBIO) Price Target Raised to $56 by H.C. Wainwright | - GuruFocus
Transcript : BridgeBio Pharma, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
BridgeBio Pharma (BBIO) Sees Price Target Increase by HC Wainwright & Co. | BBIO Stock News - GuruFocus
BridgeBio (BBIO) Price Target Raised to $56 by H.C. Wainwright | BBIO Stock News - GuruFocus
Breakthrough Growth in Transthyretin Amyloid Cardiomyopathy - openPR.com
Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday - MSN
BridgeBio Pharma stock hits 52-week high at $39.58 By Investing.com - Investing.com South Africa
BridgeBio Pharma stock hits 52-week high at $39.58 - Investing.com Australia
BMO Maintains Hold on BridgeBio (BBIO) Amid Intensifying Competition - MSN
Piper Sandler maintains overweight rating on BridgeBio Pharma stock - Investing.com
Piper Sandler maintains overweight rating on BridgeBio Pharma stock By Investing.com - Investing.com UK
BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug - MSN
BridgeBio price target raised to $42 from $37 at BMO Capital - Yahoo Finance
BMO Capital raises BridgeBio Pharma stock price target to $42 By Investing.com - Investing.com UK
BridgeBio (BBIO) Target Price Raised by BMO Capital | BBIO Stock News - GuruFocus
Exploring High Growth Tech Stocks In The US Market - simplywall.st
BridgeBio: New Data Bolsters The Bull Case (NASDAQ:BBIO) - Seeking Alpha
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | BBIO Stock News - GuruFocus
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - The Manila Times
BridgeBio Management Reveals Latest Genetic Disease Strategy at Goldman Sachs Healthcare Conference 2025 - Stock Titan
BridgeBio Pharma (NASDAQ:BBIO) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Nuveen Asset Management LLC Cuts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock - simplywall.st
BridgeBio Pharma’s SWOT analysis: stock soars on Attruby success, pipeline potential - Investing.com Nigeria
Propionic Acidemia Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Bridge Bio Pharma, HemoShear Therapeutics, Moderna Therapeutics - Barchart.com
Cetera Investment Advisers Takes $1.02 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Defense World
The Play On BridgeBio Pharma: Great Expectations For Attruby (NASDAQ:BBIO) - Seeking Alpha
BridgeBio’s Acoramidis: A Breakthrough in ATTR-CM Treatment - Insider Monkey
Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - marketscreener.com
BridgeBio (BBIO) Shares Positive Phase 3 Study Data | BBIO Stock News - GuruFocus
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM | BBIO Stock News - GuruFocus
Breakthrough: New ATTR-CM Treatment Cuts Heart Complications by 43%, Shows Fastest Clinical Benefits Ever - Stock Titan
BridgeBio’s acoramidis shows promise in ATTR-CM study By Investing.com - Investing.com Nigeria
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bridgebio Pharma Inc-Aktie (BBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Jul 01 '25 |
Sale |
42.54 |
40,000 |
1,701,400 |
975,686 |
| VIKING GLOBAL INVESTORS LP | 10% Owner |
Jun 27 '25 |
Sale |
44.00 |
3,500,000 |
154,000,000 |
18,555,375 |
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):